Cardiovascular ailments are one of the frequent modalities that are associated with T2DM. In this regard, SGLP-2 inhibitors in recent times have proven to be helpful in imparting cardiovascular protection.

It has not only benefitted in cardiovascular mortality but also renal disease, heart failure and, other defects. This exclusive interview briefs on strategies for the management of cardiovascular events in T2DM patients.